Monitor for FDA meeting outcome in mid-April and subsequent trial design announcement, which could serve as a near-term catalyst. The decision to focus on SCAC with a potentially small, fast registrational trial significantly de-risks the path to approval in a rare cancer with high unmet need.
Price Chart
Executive Summary
Oncolytics Biotech announced it will prioritize registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC) based on promising data from Cohort 4 of its GOBLET study. The company has concluded enrollment in the GOBLET trial and plans to meet with the FDA in mid-April to finalize the design of a single-arm SCAC registrational study it believes can be completed with fewer than 100 patients. Enrollment in the pancreatic cancer (PDAC) arm has been stopped at ~20 patients per arm to conserve capital.
Key Facts
- Company will focus on registrational/enabling studies in SCAC and CRC based on GOBLET Cohort 4 data
- GOBLET study enrollment concluded; no further patients will be enrolled in PDAC cohorts
- Plans to meet FDA in mid-April to align on single-arm SCAC registrational study design
- Believes trial of fewer than 100 patients may be sufficient for FDA approval in SCAC
- Has sufficient cash to execute near-term milestones without immediate material dilution
- Will continue to follow existing PDAC cohort patients and report mature data
Financial Impact
Avoids immediate material dilution; capital allocation shifted to higher-potential indications
Risk Factors
- FDA may require larger or different trial design than anticipated
- Efficacy signal in SCAC may not hold in larger study
- Terminating PDAC enrollment may limit future opportunities in pancreatic cancer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000006 |
| Document: oncygobletupdate.htm | 0001129928-26-000006 |
| Document: 0001129928-26-000006-index-headers.html | 0001129928-26-000006 |
| Document: 0001129928-26-000006-index.html | 0001129928-26-000006 |
| Document: 0001129928-26-000006.txt | 0001129928-26-000006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access